Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News & insights
Publications: 07 OCTOBER 2021
Record-breaking M&A run continues at pace
Dealmaking across the globe continues to break records, as investors take advantage of benign market conditions to deploy capital at an accelerating pace.
Read more
Publications: 06 OCTOBER 2021
Podcast: The injunction gap, proportionality and final injunctions: legislative updates in Germany
How will recent legislative updates in Germany affect patent litigation?
Read more
News: 21 SEPTEMBER 2021
Leading Tech M&A Partner Dario de Martino Joins Allen & Overy’s U.S. M&A Practice
Allen & Overy today announced that Dario de Martino has joined the firm as a partner in its M&A practice, based in New York. Dario joins from Morrison & Foerster LLP, where he was a partner in the M&A…
Read more
Publications: 15 DECEMBER 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Read moreDownload our sector brochure
